2cureX
0.386
SEK
-3.5 %
2CUREX
First North Stockholm
Medical Equipment & Services
Health Care
3 following
-3.5%
-8.53%
-15.35%
-43.65%
-31.07%
-80.15%
-97.7%
-97.2%
-94.93%
2cureX is a Danish-based biotech company with subsidiary in Hamburg, Germany. The company has made a special sensitivity test, IndiTreat, for oncology clinics that is focused on improving the outcome for cancer patients by improving the efficiency of the individual cancer treatment. IndiTreat uses a biopsy from the individual cancer patient to measure and predict the likely outcome of different available treatments, thereby assisting oncologists to choose the most effective treatment for the individual patient.
Read moreMarket cap
9.69M SEK
Turnover
8.8K SEK
Revenue
160K
EBIT %
-21,687.5 %
P/E
-
Dividend yield-%
-
Financial calendar
27/2
2025
Annual report '24
ShowingAll content types
BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING IN 2CUREX AB (PUBL)
2cureX AB Announces the Appointment of Dan Honeywell as CEO, Ushering in a New Era of commercial expansion of breakthrough precision oncology products
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools